Objectives: To evaluate the combination of CpG oligodeoxynucleotide (CpG ODN) and miltefosine for the treatment of experimental visceral leishmaniasis (VL).
Introduction
Leishmaniasis is an emergent disease in tropical and subtropical regions, with high morbidity and mortality. It is caused by parasitic protozoans of the genus Leishmania. Available antileishmanial therapy is inadequate and suffers from several drawbacks. First-line therapy includes sodium stibogluconate (SbV), to which unfortunately resistance has developed in some areas of Bihar where failure rates of up to 65% have been reported, and the use of antimony has been abandoned. 1 Pentamidine also went out of favour for treatment of visceral leishmaniasis (VL). 2 The use of liposomal amphotericin B is limited due to the high market price. 3 A major milestone in the chemotherapy of VL was the discovery of miltefosine, an analogue of phosphatidylcholine initially developed as an anti-cancer agent. 4 It is an effective oral drug, but its use in women of child-bearing age is restricted due to teratogenicity. In addition, it has a long half-life, which might encourage the emergence of resistance once its use becomes widespread. 5 The efficacy of treatment of Leishmania is compromised due to suppression of immune function during the course of infection. 6 It is usually associated with a depression of Th1 cells and preferential expansion of Th2 cells and, accordingly, skewing of T helper cells towards a Th1 response is considered a promising therapeutic strategy. In the present work, we explore a combination of CpG oligodeoxynucleotide (CpG ODN) and miltefosine, at a subcurative dose, for the treatment of experimental VL in rodent models. CpG ODNs are a class of pharmacotherapeutic agent characterized by the presence of an unmethylated CG dinucleotide in specific base sequence contexts (CpG motif). These CpG motifs are not seen in eukaryotic DNA, but are present in bacterial DNA to which they confer immunostimulatory properties. 7 These properties include induction of a Th1-type response with prominent release of interferon 8 CpG ODNs have demonstrated substantial potential as vaccine adjuvants, and as mono-or combination therapies for the treatment of cancer, infectious diseases and allergic diseases. 9 They have also shown effects in multiple rodent and primate models of asthma and other allergic diseases, with encouraging results in some early human clinical trials. 10 The applicability of CpG ODN has also been exploited in the field of leishmaniasis, especially as an immunomodulator and adjuvant with various immunogens. 11 -14 There are several studies using endogenous biologicals, microbial derivatives or synthetic compounds in both animals and humans. Among the most frequently used immunomodulators are BCG (bacille Calmette -Guèrin), muramyl dipeptide, trehalose mycolate, glucan, tuftsin and protein A, which have a direct effect on macrophages. 15 We have studied the antileishmanial efficacy of the combination of CpG ODN and miltefosine in mouse and hamster models. The hamster model is known to closely mimic the condition of human VL better than any other animal model. The study involves use of free as well as liposomal CpG ODN in combination with miltefosine. To establish the effect of CpG ODN on the immune functions of the host, immunological parameters, namely Th1/Th2 cytokines, production of reactive oxygen species (ROS), reactive nitrogen species (RNS) and H 2 O 2 , and phagocytosis, were monitored. The results were compared with untreated animals, which served as controls.
Materials and methods

Parasite
The WHO reference strain of L. donovani (MHOM/IN/80/Dd8), obtained from Imperial College, London (UK), was maintained as promastigotes in vitro and as amastigotes in golden hamsters. Promastigotes of L. donovani were cultivated in medium 199 (Sigma-Aldrich) supplemented with 0.1% gentamicin (Biovaccines Private Ltd, Chevella, India) and 10% fetal calf serum. 16 
Animals
BALB/c mice (18 -20 g ) and inbred hamsters (40 -45 g) of both sexes were used for the study. All the experiments were conducted in compliance with the Institutional Animal Ethics Committee (IAEC) guidelines for the use and handling of animals. Throughout the study, the animals were housed in climate-controlled (23+28C; relative humidity: 60%) and photoperiod-controlled (12 h light-dark cycles) animal quarters. They were fed standard rodent pellets supplemented with grain and had free access to drinking water.
CpG ODN
Fully phosphothioated CpG ODN (18 -24 bp in length) (5 ′ -TCC ATG ACG TTC CTG ACG TT-3 ′ ) also known as ODN-1826 (mol. wt 6364.1 g/mol) was supplied by Trilink Biotechnologies and was used for this study.
Miltefosine
Miltefosine was purchased from SynphaBase AG (Switzerland). For the in vivo part of the study, miltefosine was dissolved in deionized water.
Liposome preparation
Liposomes containing CpG ODN were prepared by the dehydrationrehydration vesicle (DRV) method. 17, 18 The lipid phase consists of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (6 mM) and cholesterol (2 mM) dissolved in chloroform/methanol (2:1, v/v) in a flatbottomed tube. The solvent was removed by slow evaporation under nitrogen with deposition of a thin film of lipid on the surface of the tube. The tube was dried to remove any trace of solvent. The lipid film was then hydrated and dispersed in a solution of an appropriate quantity of CpG ODN in distilled water and processed to get the desired preparation of liposomal CpG ODN. The percentage incorporation of CpG into the liposomes was determined using UV absorption at 260 nm and the concentration of CpG ODN in the liposomes was adjusted to the desired concentration prior to administration.
Infection of mice and antileishmanial efficacy evaluation BALB/c mice were infected intracardially with 2×10 7 L. donovani (MHOM/ IN/80/Dd8) amastigotes and randomly sorted into groups of five or six animals each. The same number of mice was kept as an untreated control group. Mice were dosed by intraperitoneal (ip) and oral (po) routes at 7 days post-infection for 5 consecutive days. Animals were sacrificed on day 3 post-treatment (day 14 post-infection). Impression smears of livers were prepared, methanol fixed and stained with 10% Giemsa stain in phosphate-buffered saline (PBS). The number of amastigotes per 500 liver cell nuclei was determined. The percentage inhibition (PI) was calculated for all drug-treated groups in relation to the untreated group.
Infection of hamsters and antileishmanial efficacy evaluation
The evaluation in hamsters was carried out in accordance with the method described by Bhatnagar et al. 19 Five or six animals were used for each agent. The same number of hamsters was kept as an untreated control group. The drug treatment was given by ip and po routes. To assess the effect of drugs, spleen biopsy was performed on each animal on day 7 post-treatment and amastigote counts were assessed by Giemsa staining. 16 The PI was calculated for all drug-treated groups in relation to the untreated group.
Optimization of CpG ODN and miltefosine dose regimens against L. donovani/BALB/c mouse and L. donovani/ hamster models Each group consisting of five or six infected animals in two replicates for each species were used. The CpG ODN was administered at dose concentrations of 0.5, 1, 2 and 5 nM prepared in deionized water by the ip route for dose optimization. A 1 nM dose of CpG ODN was found to be the most appropriate for combination studies in both of the species. Miltefosine was given at doses ranging from 20 to 1.25 mg/kg in mice and from 40 to 2.5 mg/kg in hamsters for 5 days by the po route to select the subcurative dose. The subcurative dose selected was 2.5 and 5 mg/kg in mice and hamsters, respectively.
Evaluation of free CpG ODN and liposomal CpG ODN alone and in combination with miltefosine in mice and hamsters Seven groups of mice each consisting of five or six animals in two replicates were used for these experiments. Group I received free CpG ODN (1 nM) by the ip route, group II received free CpG ODN (1 nM) +miltefosine (2.5 mg/kg×5 days), group III received liposomal CpG ODN (1 nM), group IV received liposomal CpG ODN (1 nM) +miltefosine (2.5 mg/kg×5 days), groups V and VI received subcurative (2.5 mg/kg) and curative (10 mg/ kg) miltefosine po for 5 days, respectively, and group VII received PBS and served as a control. The same protocol was adopted for hamsters, where miltefosine was given at doses of 5 mg/kg×5 days (subcurative) and 20 mg/kg×5 days (curative). The PI was calculated for all drug-treated groups in relation to the non-treated group.
Evaluation of Th1/Th2 cytokines in mice
Serum samples from animals of treated and untreated control groups were analysed for various Th1 [tumour necrosis factor (TNF), IFN-g and IL-2] and Th2 (IL-4 and IL-5) cytokines using a CBA mouse Th1/Th2 cytokine assay kit (BD Biosciences) in accordance with the manufacturer's instructions. The kit is provided with five bead populations with distinct fluorescence intensities that have been coated with capture antibodies specific for IL-4, IL-5, IFN-g, TNF and IL-2 proteins. The recombinant standards and samples were mixed with the cytokine capture beads and incubated (at room temperature for 2 h, protected from the light) with phycoerythrin (PE)-conjugated detection antibodies to form sandwich complexes. The intensity of PE fluorescence of each sandwich complex reveals the concentration of that cytokine. Samples were read using FACS Calibur and BD FACS Comp software. Data were evaluated for five parameters, namely FSC, SSC, FL1, FL2 and FL3, and presented as mean fluorescence signals.
Biochemical analysis for measuring production of ROS, RNS and H 2 O 2
For fluorometric detection of toxic oxygen (ROS and H 2 O 2 ) and nitrogen (RNS) metabolites, dichlorofluorescein diacetate (DCFH) and diaminofluorescein-2-diacetate (DAF2DA) dyes were used, respectively. 4a-Phorbol 12-myristate 13-acetate (PMA) was used as an inducer for production of oxygen metabolites. The decrease in fluorescence of inhibitor-treated peritoneal exudate cells (PECs) was measured and compared with that of untreated PECs. Inhibitors used were pentoxifylline (PTX), which inhibits NADP-oxidase and is required for superoxide ion production, N-nitro-L-arginine methyl ester (L-NAME), which inhibits nitric oxide (NO) synthase and is essential for production of NO 2 , and NaN 3 , which inhibits catalase and is required for production of H 2 O 2 . 20 A drop in the fluorescence of inhibitor is an indicator of the concentration of its substrate in the cell suspension.
PECs were extracted from animals of all the experimental groups and layered at 1×10 6 cells/mL per well in 24-well tissue culture plates and incubated at 378C/5% CO 2 for 24 h. The non-adherent macrophages were removed by washing. Cells were incubated with inhibitors (L-NAME, 10 mM; PTX, 10 mM; and NaN 3 ,10 mM) for 1 h at 378C/5% CO 2 followed by induction with PMA (20 mM) and incubation for 1 h. Finally, dye (DCFH or DAF2DA) at a concentration of 10 mM was added to each well and incubated for 30 min. Each step was followed by appropriate washings. Free radicals generated from peritoneal macrophages oxidized non-fluorescent forms of dyes to fluorescent forms. Fluorescent signals from the dyes were read using Cell Quest FACS Caliber (Becton Dickinson) with an FL1 UV band pass filter (excitation at 488 nm and emission at 510-513+30 nm).
Phagocytosis assay
A flow cytometry based method was used to study the phagocytic activity of macrophages. 21 PECs of each experimental group were seeded at 1×10 6 cells/mL per well in 24-well tissue culture plates and incubated at 378C/5% CO 2 for 24 h. The non-adherent macrophages were removed by washing and incubated with 10 mM fluorescein isothiocyanate-labelled bacteria (1:10 ratio) for 30 min at 378C, except control wells. After incubation, excess non-phagocytized bacteria were removed by washing. The cells were collected in tubes and phagocytosis was observed using FACS Caliber with an FL1 UV band pass filter (excitation at 488 nm and emission at 510-513+30 nm). The results were presented as the phagocytic index, which is the ratio of the mean OD of stimulated cells to the mean OD of unstimulated cells.
Study of cell-mediated immune response in hamsters (lymphocyte proliferation test)
Mesenteric lymph nodes of hamsters from all groups were taken out after killing with an overdose of anaesthetic ether. A cell suspension was prepared from the nodes and incubated with 25 mg/mL soluble Leishmania antigen as described by Shrivastava et al. 22 Concanavalin A (5 mg/mL) was used as a standard stimulant (data not shown). The results were expressed as the stimulation index (SI), which is the ratio of the mean cpm of stimulated culture to that of unstimulated culture.
Statistical analysis
Results are presented as means+SD of two experiments and analysis of data was carried out using Bonferroni's multiple comparison tests and Dunnett's multiple comparison tests. Differences with P values ,0.05 were considered significant. Subcurative dose was determined by Probit analysis. 23 
Results
Dose optimization of CpG ODN in mice
Various doses of CpG ODN were explored and the best antileishmanial efficacy was witnessed at a dose of 1 nM/single shot/ip (41.1% inhibition of parasite multiplication), followed by gradually decreasing efficacy with 2 and 5 nM doses, namely 22% and 18% inhibition of parasite multiplication, respectively. A 0.5 nM dose was also tested (data not shown), but it showed no efficacy. Based on the results, 1 nM/single shot/ip was selected for the combination trial.
Dose optimization of miltefosine in mice
Miltefosine was evaluated at various doses ranging from 20 to 1.25 mg/kg for 5 days by the po route, in order to select the subcurative dose. Parasite inhibition observed at 20 mg/kg was 100%, followed by 90%, 70.5%, 48.8% and 34.5% at doses of 10, 5, 2.5 and 1.25 mg/kg, respectively. The best dose for the combination trial was selected as 2.5 mg/kg.
Combination therapy (CpG ODN1 miltefosine) in mice
Results of combination therapy of free and liposomal CpG ODN with miltefosine are presented in Figure 1 . Free CpG ODN showed an efficacy of 42%, which was moderately enhanced to 55.2% by liposomal encapsulation (P, 0.01). Miltefosine alone exhibited parasite inhibition of 46%. However, when free CpG ODN was given with a subcurative dose of miltefosine, parasite inhibition increased from 46% to 65% (P,0.01) and liposomal CpG ODN further enhanced the efficacy up to 85% (P,0.001). Interestingly, the effectiveness of this combination was very close to that of the curative dose (10 mg/kg×5 days) of miltefosine (90.2%).
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Biochemical assays in mice
The results are displayed in Figure S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/). Mice administered free CpG ODN showed moderate NO, ROS and H 2 O 2 production. Free CpG ODN, when co-administered with miltefosine, enhanced the production of NO and H 2 O 2 . ROS production in this group, however, remained unaffected. Liposomal CpG ODN showed significant NO production and moderate ROS and H 2 O 2 production. However, when it was combined with miltefosine, remarkable production of NO, ROS and H 2 O 2 was observed. Miltefosine showed significant NO and H 2 O 2 production and moderate ROS production.
Phagocytosis in mice
From the results presented in Figure 2 , it was observed that cells of untreated control mice showed the lowest phagocytic index (12.5+9.0). Treatment with miltefosine moderately increased the phagocytic index to 29.4 (P,0.01). Mice treated with free CpG ODN also showed a similar index, 30.0+5.0 (P,0.01). Free CpG ODN when co-administered with miltefosine enhanced the index to 45.5+5.0 (P,0.001). Liposomal CpG ODN gave a phagocytic index of 37.5+4.0 (P,0.01) and when given with miltefosine there was a remarkable increase in the index up to 55.1+3.0 (P,0.001), which was almost equal to the phagocytic index of normal uninfected animals (60+3.0).
Cell-mediated immune response in mice
Results are displayed in Figure 3 . More than a 3-fold rise in TNF and IL-2 production and a moderate rise in IFN-g production were observed after liposomal encapsulation of CpG ODN. Free CpG ODN when combined with miltefosine gave a 2-fold rise in both TNF and IFN-g. Significant enhancement of IFN-g production was witnessed in animals co-administered liposomal CpG ODN and miltefosine. Briefly, we can say that combination therapy involving free or liposomal CpG ODN with miltefosine increased Th1 (TNF, IFN-g and IL-2) cytokine levels and downregulated Th2 (IL-4 and IL-5) cytokines. Animals treated with miltefosine alone showed a moderately enhanced Th1 response. 
Dose optimization of CpG ODN in hamsters
The best antileishmanial efficacy was observed at a dose of 1 nM/single shot/ip, i.e. 55.7% inhibition of parasite multiplication, followed by gradually decreasing efficacy at 2 and 5 nM doses, namely 38.1% and 33.3% inhibition of parasite multiplication, respectively.
Dose optimization of miltefosine in hamsters
Miltefosine was administered at various doses ranging from 40 to 2.5 mg/kg for 5 days by the po route, in order to select the subcurative dose. Parasite inhibition observed at 40 mg/kg was 100% followed by 92%, 83.0%, 55.5% and 35.8% at doses of 20, 10, 5 and 2.5 mg/kg. The best dose for combination studies was selected as 5 mg/kg.
Combination therapy (CpG ODN1 miltefosine) in hamsters
Results of this study are presented in Figure 1 . Free CpG ODN showed an efficacy of 32.3%, which was moderately enhanced to 50.9% by liposomal encapsulation (P,0.01). Miltefosine alone exhibited parasite inhibition of 50%. However, when free CpG ODN was given with a suboptimal dose of miltefosine, the parasite inhibition increased from 50% to 63.1% (P,0.001) and liposomal CpG ODN further enhanced the efficacy up to 81.7% (P,0.001). The efficacy of this combination was close to the efficacy of the curative dose (20 mg/kg×5 days) of miltefosine (91.8%).
Biochemical assays in hamsters
The results are displayed in Figure S2 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/). Animals administered free CpG ODN showed significant NO production. Free CpG ODN, when co-administered with miltefosine, enhanced production of ROS as well as H 2 O 2 , along with significant NO production. Liposomal CpG ODN alone and in combination with miltefosine showed remarkable production of H 2 O 2 along with NO. Miltefosine alone resulted in significant NO production.
Phagocytosis in hamsters
Results are presented in Figure 2 . The cells of untreated control hamsters showed the lowest phagocytic index (17+5.0). Miltefosine-treated animals exhibited a moderately increased index of 36.5+13.2 (P,0.01). Hamsters treated with free CpG ODN showed a phagocytic index of 40.2+7.9 (P,0.01); when co-administered with miltefosine, the index was enhanced to 46.5+9.9 (P,0.01). Liposomal CpG ODN showed a phagocytic index of 65.2+5.5 (P,0.01) and, when given with miltefosine, a remarkable increase in index up to 78.3+5.2 (P,0.001) was observed, which was almost equal to the phagocytic index of normal uninfected animals (88+5.0).
Lymphocyte proliferation test in hamsters
Detailed results are shown in Figure 4 . 
Discussion
In view of the severe immunosuppression in VL, a rational approach to effectively combat the parasitic scourge would be to enhance the immune status of the host. 24, 25 Use of CpG ODN has been reported in the field of leishmaniasis especially as an immunomodulator and adjuvant with various immunogens. 11 -14 Keeping this in mind, we have explored the adjunct effect of fully thioated CpG ODN (free and liposomal) on the efficacy of miltefosine using L. donovani/BALB/c mouse and L. donovani/hamster models. Our results clearly show that liposomal encapsulation enhances the antileishmanial efficacy of free CpG ODN. Co-administered liposomal CpG ODN and miltefosine showed a better inhibitory effect than free CpG Sane et al.
ODN+ miltefosine, free CpG ODN alone or miltefosine alone. In order to explore the effect of liposomal lipids on parasite inhibition, an empty liposome preparation was also administered in a separate experiment. We did not observe any improvement over the untreated infected control groups (data not shown). This is in agreement with a previous report by Badiee et al. 13 Results of immunological assays in mice suggested that CpG ODN potentiated cell-mediated immunity, evident from a significant rise in Th1 cytokines and a down-regulation of Th2 cytokines. Liposomal encapsulation of CpG ODN enhanced IL-2, TNF and IFN-g levels. In biochemical assays, liposomal CpG ODN combined with miltefosine resulted in a remarkable production of NO, ROS and H 2 O 2 . Thus, the promising antileishmanial efficacy of liposomal CpG ODN+ miltefosine is strongly supported by enhancement of Th1 cytokines as well as NO, ROS and H 2 O 2 levels. Datta et al., 12 have also reported that liposomal preparations of CpG ODN are more potent at eliminating Leishmania parasites than free CpG ODN. We have demonstrated the application of liposomal CpG ODN in combination with miltefosine as a novel therapeutic approach for a safer treatment of leishmaniasis using a significantly reduced dose of miltefosine in mouse and hamster models. The antileishmanial efficacy of this combination provides scope for further development in human VL. CpG ODN in leishmanial chemotherapy
